Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Quest LaboratoriesNSE:QUESTLAB -2.53%44 3-Year EPS without NRI Growth Rate is 25.30% as of Mar. 2026, which is 14% below its 10-year median of 29.50. GuruFocus rates NSE:QUESTLAB with a GF Score™ of 44/100. The stock has 5 warning signs investors should review. Among 790 Drug Manufacturers companies, Quest Laboratories ranks better than 71.9% on this metric.
During the past 12 months, Quest Laboratories's average EPS without NRI Growth Rate was 10.60% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 25.30% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 58.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 6 years, the highest 3-Year average EPS without NRI Growth Rate of Quest Laboratories was 116.10% per year. The lowest was 25.30% per year. And the median was 29.50% per year.
Quest Laboratories (NSE:QUESTLAB) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Quest Laboratories 3-Year EPS without NRI Growth Rate Related Terms
NSE:QUESTLAB vs LLY, JNJ, ABBV: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - General subindustry, Quest Laboratories's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quest Laboratories 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Quest Laboratories's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Quest Laboratories's 3-Year EPS without NRI Growth Rate falls into.
Quest Laboratories 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 25.30% mean?
Quest Laboratories (NSE:QUESTLAB) has a 3-Year EPS without NRI Growth Rate of 25.30% as of Mar. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Quest Laboratories and its competitors. This is 14% below median its historical median of 29.50. Over the past decade, Quest Laboratories' 3-Year EPS without NRI Growth Rate has ranged from 25.30 to 116.10. According to the industry distribution chart, Quest Laboratories ranks #222 out of 790 companies in the Drug Manufacturers industry, placing it in the top 28.1%.
Is Quest Laboratories' 3-Year EPS without NRI Growth Rate too high?
Quest Laboratories' current 3-Year EPS without NRI Growth Rate of 25.30% is 14% below median its 10-year median of 29.50. Over the past 10 years, this metric has ranged from a low of 25.30 to a high of 116.10. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.60. Quest Laboratories' value of 25.30% is 163.5% above this industry median. Based on the distribution chart, Quest Laboratories ranks #222 out of 790 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Quest Laboratories has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Quest Laboratories' 3-Year EPS without NRI Growth Rate compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Quest Laboratories ranks #222 out of 790 companies for 3-Year EPS without NRI Growth Rate. This puts Quest Laboratories in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 9.60. Quest Laboratories' value of 25.30% is 163.5% above this benchmark. Historically, Quest Laboratories' own 3-Year EPS without NRI Growth Rate has ranged from 25.30 to 116.10 over the past decade. While the company's 10-year median is 29.50 vs. the industry median of 9.60, Quest Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.60, based on 790 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Quest Laboratories's current 3-Year EPS without NRI Growth Rate of 25.30% is 163.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Quest Laboratories and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quest Laboratories's current 3-Year EPS without NRI Growth Rate is 25.30%, which is 14% below median its own 10-year median of 29.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest Laboratories stock overvalued right now?
Quest Laboratories (NSE:QUESTLAB) has a current 3-Year EPS without NRI Growth Rate of 25.30%. The current 3-Year EPS without NRI Growth Rate is 25.30%, which is 14% below median its 10-year median of 29.50 and 163.5% above the Drug Manufacturers industry median of 9.60. Quest Laboratories' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Quest Laboratories (NSE:QUESTLAB), the current 3-Year EPS without NRI Growth Rate is 25.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quest Laboratories Ltd is engaged in the business of manufacturing pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. It produces various products, comprising ethical drugs, generic drugs, and over-the-counter drugs, and is also available in various forms such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids, among others. The company operates in a single segment of Drugs and Chemicals.
44GF Score
Get the complete analysis for NSE:QUESTLAB
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QUESTLAB has been successfully added to your 
